News

  • 8 November 2011

    Abbott announces results of Humira trials

    Abbott has announced the data from Premier and DE019 Phase III studies that investigated Humira (adalimumab) plus methotrexate for up to eight years in patients with early moderate to severe...

Close
Close
Close

Go Top